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How do I identify HMB?
In the UK, one in 20 women of reproductive age consults their GP annually because of HMB. This accounts for 20% of outpatient gynaecology referrals (Bhattacharya et al., 2011) .
Most women describe significantly more blood loss than usual, with or without flooding, which interferes with their physical, emotional, social and material quality of life (NICE, 2007) . Secondary effects such as tiredness and anaemia are common. A woman's own perception is the usual indication for medical and surgical intervention.
What history should I take?
Aspects include the nature of bleeding, symptoms that might suggest structural or histological abnormality, impact on quality of life and factors that may determine treatment options, e.g. co-morbidities. The menstrual cycle and bleed length varies between women and is normally distributed (Davis et al., 2005) . However, with HMB the length of menstruation is increased significantly up to several weeks with no relief.
If 'red flag' symptoms, such as intermenstrual bleeding, postcoital bleeding, pelvic pain and/or pressure symptoms, are present, then examine the patient, arrange a pelvic ultrasound and refer to a gynaecologist (NICE, 2007). 3. What are the medical management options?
If the history suggests HMB without structural or histological abnormality, then pharmaceutical treatment can be started without carrying out a physical examination or other investigations at the initial consultation in primary care (NICE, 2007) .
Treatments should be considered in the following order.
(i) Levonorgestrel-releasing intrauterine system, provided at least 12 months use is anticipated in those not wanting to conceive immediately. It works locally by causing endometrial atrophy, while minimising systemic side-effects. An ultrasound scan to assess suitability is usually carried out prior to insertion. (ii) Medical options.
. Tranexamic acid: This is an anti-fibrinolytic agent.
The maximum dose is 3-4 grams daily for 4 days from the onset of bleeding. . Non-steroidal anti-inflammatories (NSAIDs): These reduce blood loss (Lethaby, Duckitt, & Farquhar, 2013) and help dysmenorrhoea. They can be combined with anti-fibrinolytics. An example is mefenamic acid 500 mg three times daily, taken from the onset or just before bleeding, until symptoms resolve. . Combined oral contraceptives: Women taking the pill tend to experience lighter, pain-free bleeds, which arrive at predictable intervals. 
How do you best manage acute HMB?
The choice of treatment depends on the clinical stability, suspected aetiology, desire for future fertility and co-morbidities. The two main objectives are to control the current episode of HMB and to reduce menstrual blood loss in subsequent cycles (ACOG, 2013) .
If the woman is clinically stable and not pregnant, a combination of both hormonal and non-hormonal treatment should be tried after a pelvic examination. If this fails, an urgent gynaecology referral to explore surgical management should be made. 
